MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
NASDAQ:MDXG - US6024961012 - Common Stock
7.135 USD
+0.1 (+1.49%)
Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 549 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDXG has a Return On Assets of 11.05%. This is amongst the best in the industry. MDXG outperforms 93.62% of its industry peers.
The Return On Equity of MDXG (14.85%) is better than 94.17% of its industry peers.
The Return On Invested Capital of MDXG (13.37%) is better than 95.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROIC | 13.37% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a better Profit Margin (8.84%) than 92.17% of its industry peers.
With an excellent Operating Margin value of 12.07%, MDXG belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
MDXG's Operating Margin has been stable in the last couple of years.
MDXG has a better Gross Margin (81.45%) than 85.61% of its industry peers.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
MDXG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 10.47 indicates that MDXG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.47, MDXG belongs to the top of the industry, outperforming 86.89% of the companies in the same industry.
MDXG has a debt to FCF ratio of 0.32. This is a very positive value and a sign of high solvency as it would only need 0.32 years to pay back of all of its debts.
MDXG has a better Debt to FCF ratio (0.32) than 95.63% of its industry peers.
MDXG has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MDXG (0.08) is worse than 63.02% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Altman-Z | 10.47 |
ROIC/WACC1.37
WACC9.79%
2.3 Liquidity
MDXG has a Current Ratio of 4.39. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio (4.39) which is in line with its industry peers.
A Quick Ratio of 3.90 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio of 3.90. This is comparable to the rest of the industry: MDXG outperforms 46.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.39%.
The Revenue has been growing slightly by 6.85% in the past year.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
3.2 Future
MDXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.19% yearly.
The Revenue is expected to grow by 12.54% on average over the next years. This is quite good.
EPS Next Y-11.19%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MDXG is valuated quite expensively with a Price/Earnings ratio of 27.44.
MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 93.26% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDXG to the average of the S&P500 Index (26.76), we can say MDXG is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 21.20, the valuation of MDXG can be described as rather expensive.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 92.35% of the companies in the same industry.
MDXG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.91, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.44 | ||
| Fwd PE | 21.2 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.72% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 94.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.39 | ||
| EV/EBITDA | 17.26 |
4.3 Compensation for Growth
The decent profitability rating of MDXG may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.74%
EPS Next 3Y8.19%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MDXG (8/22/2025, 9:33:10 AM)
7.135
+0.1 (+1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.37%
Inst Owner Change2.43%
Ins Owners1.84%
Ins Owner Change1.26%
Market Cap1.06B
Analysts81.82
Price Target12.44 (74.35%)
Short Float %3.44%
Short Ratio6.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.25%
Min EPS beat(2)6.95%
Max EPS beat(2)81.55%
EPS beat(4)3
Avg EPS beat(4)17%
Min EPS beat(4)-31.92%
Max EPS beat(4)81.55%
EPS beat(8)7
Avg EPS beat(8)68.99%
EPS beat(12)10
Avg EPS beat(12)59.73%
EPS beat(16)12
Avg EPS beat(16)49.94%
Revenue beat(2)2
Avg Revenue beat(2)3.5%
Min Revenue beat(2)0.32%
Max Revenue beat(2)6.68%
Revenue beat(4)3
Avg Revenue beat(4)2.13%
Min Revenue beat(4)-0.35%
Max Revenue beat(4)6.68%
Revenue beat(8)6
Avg Revenue beat(8)1.52%
Revenue beat(12)8
Avg Revenue beat(12)2.12%
Revenue beat(16)12
Avg Revenue beat(16)2.46%
PT rev (1m)1.67%
PT rev (3m)1.67%
EPS NQ rev (1m)20.69%
EPS NQ rev (3m)-15.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.18%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)-1.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.44 | ||
| Fwd PE | 21.2 | ||
| P/S | 2.9 | ||
| P/FCF | 18.39 | ||
| P/OCF | 18.16 | ||
| P/B | 4.87 | ||
| P/tB | 5.7 | ||
| EV/EBITDA | 17.26 |
EPS(TTM)0.26
EY3.64%
EPS(NY)0.34
Fwd EY4.72%
FCF(TTM)0.39
FCFY5.44%
OCF(TTM)0.39
OCFY5.51%
SpS2.46
BVpS1.46
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROCE | 18.24% | ||
| ROIC | 13.37% | ||
| ROICexc | 26.4% | ||
| ROICexgc | 35.58% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% | ||
| FCFM | 15.78% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 6.78% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | 28.3 | ||
| Cash Conversion | 106.77% | ||
| Profit Quality | 178.44% | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 10.47 |
F-Score5
WACC9.79%
ROIC/WACC1.37
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-11.19%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
EBIT growth 1Y-29.45%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year32.1%
EBIT Next 3Y17.11%
EBIT Next 5YN/A
FCF growth 1Y1521.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6349.89%
OCF growth 3YN/A
OCF growth 5YN/A